| 3.36 Delayed Data As of Nov 15 |  +0.14 / +4.35%Today’s Change | 2.99 Today|||52-Week Range 10.45 | -39.24% Year-to-Date |
| $100 Million Loan Overshadows Akebia Therapeutics' Q3 Earnings Miss Nov 12 / MotleyFool.com - Paid Partner Content | Akebia Therapeutics Inc (AKBA) Q3 2019 Earnings Call Transcript Nov 12 / MotleyFool.com - Paid Partner Content |
| Previous close | 3.22 |
| Today’s open | 3.26 |
| Day’s range | 3.23 - 3.43 |
| Volume | 1,707,750 |
| Average volume (3 months) | 841,531 |
| Market cap | $400.8M |
| Earnings growth (last year) | -39.77% |
| Earnings growth (this year) | -- |
| Earnings growth (next 5 years) | +15.80% |
| Revenue growth (last year) | +16.72% |
| P/E ratio | NM |
| Price/Sales | 1.54 |
| Price/Book | 0.62 |
| Today’s change | Today’s % change | |
|---|---|---|
| BSTCBiospecifics Technol... | +0.06 | +0.11% |
| REPHRecro Pharma Inc | +0.59 | +3.57% |
| ARDXArdelyx Inc | -0.01 | -0.16% |
| KRTXKaruna Therapeutics ... | +0.29 | +1.67% |
| Next reporting date | March 4, 2020 |
| EPS forecast (this quarter) | -$0.50 |
| Annual revenue (last year) | $207.7M |
| Annual profit (last year) | -$143.6M |
| Net profit margin | -69.12% |
Sector Health Technology |
Industry Biotechnology |
No executives to display |
Corporate headquarters Cambridge, Massachusetts |
